Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGKA | P23743 | 1/20 | 0.68 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.61 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.61 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.61 |
| ▸ | NAAA | Q02083 | 1/20 | 0.57 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.56 |
| ▸ | HTR2C | P28335 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 3/20 | 0.53 |
| ▸ | PAM | P19021 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7332890 | 1.00 | DGKA (0.68) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7509234 | 1.00 | DGKA (0.68) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7836216 | 0.98 | DGKA (0.71) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7839300 | 0.98 | DGKA (0.71) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL10892401 | 0.98 | DGKA (0.71) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7838000 | 0.98 | DGKA (0.71) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL1888899 | 0.98 | DGKA (0.71) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7840375 | 0.98 | DGKA (0.71) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL7839329 | 0.98 | DGKA (0.71) | DGKAPRSS1PRSS2PRSS3NAAA | |
| SCHEMBL6880430 | 0.98 | DGKA (0.71) | DGKAPRSS1PRSS2PRSS3NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-106970503-B | Photosensitive composition | 东京应化工业株式会社 | 2022-02-01 | — | — | CN | disclosed |
| CN-111278896-A | Thermosetting resin composition and method for producing same | 堺化学工业株式会社 | 2020-06-12 | — | — | CN | disclosed |
| EP-2665775-B1 | UV STABILIZATION OF ISOSORBIDE POLYCARBONATES | SABIC GLOBAL TECHNOLOGIES BV (NL) | 2016-11-16 | — | — | EP | disclosed |
| US-8633265-B2 | UV stabilization of isosorbide polycarbonates | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2014-01-21 | — | — | US | disclosed |
| EP-2665775-A1 | UV STABILIZATION OF ISOSORBIDE POLYCARBONATES | SABIC Innovative Plastics IP B.V. (NL) | 2013-11-27 | — | — | EP | disclosed |
| US-8551999-B2 | Heterocyclic compound and pharmaceutical composition thereof | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-10-08 | — | — | US | disclosed |
| WO-2012098513-A1 | UV STABILIZATION OF ISOSORBIDE POLYCARBONATES | SABIC INNOVATIVE PLASTICS IP B.V. (NL) | 2012-07-26 | — | — | WO | disclosed |
| US-20120184651-A1 | UV Stabilization of Isosorbide Polycarbonates | SHPP GLOBAL TECHNOLOGIES B.V. (NL) | 2012-07-19 | — | — | US | disclosed |
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-10-14 | — | — | US | disclosed |
| EP-2207773-A2 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | Otsuka Pharmaceutical Co., Ltd. (JP) | 2010-07-21 | — | — | EP | disclosed |
| EP-0565132-A2 | Benzoheterocyclic compounds | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1993-10-13 | — | — | EP | disclosed |
| US-5192779-A | Substituted-acetamide compound and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1993-03-09 | — | — | US | disclosed |
| US-5155114-A | Treating or preventing renal toxicity, nephrosis, nephritis | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-10-13 | — | — | US | disclosed |
| EP-0497258-A2 | Use of adenosine antagonists in the prevention and treatment of pancreatitis and ulcer | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1992-08-05 | — | — | EP | disclosed |
| US-5066680-A | NOVEL SUBSTITUTED-ACETAMIDE COMPOUND AND A PROCESS FOR THE PREPARATION THEREOF | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-11-19 | — | — | US | disclosed |
| US-4985444-A | Pyrazolopyridine compound and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1991-01-15 | — | — | US | disclosed |
| EP-0383256-A2 | A novel substituted-acetamide compound and a process for the preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-22 | — | — | EP | disclosed |
| EP-0379979-A1 | Pyrazolopyridine compounds and processes for preparation thereof | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1990-08-01 | — | — | EP | disclosed |
| EP-0287951-A2 | 7-Piperazinyl- or 7-Morpholino-4-oxo-quinoline-3-carboxylic acid derivatives, their preparation and their use as antimicrobial agents | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1988-10-26 | — | — | EP | disclosed |
| EP-0220516-A1 | Process for the production of aromatic carboxylic-acid chlorides | BAYER AG (DE) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100261720-A1 | HETEROCYCLIC COMPOUND AND PHARMACEUTICAL COMPOSITION THEREOF | COL1A1, COL2A1, COL14A1 | DGKA 4865/4885PRSS1 2116/4885PRSS2 3602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.